Logo 1 Logo 2

Clinical Trial Details

Trial ID: L5621
Source ID: NCT05189015
Associated Drug: Olmesartan
Title: Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension
Acronym: Ang(1-7)
Status: COMPLETED
Study Results: NO
Results:
Conditions: Angiotensin/Renin/Aldosterone Hypertension|Hypertension|Diabetes Mellitus, Type 2
Interventions: DRUG: Olmesartan
Outcome Measures: Primary: angiotensin(1-7), Changes of serum angiotensin(1-7) at week 24 from baseline, 24 weeks | Secondary: Blood pressure, Change in blood pressure from baseline to week 24, 24 weeks|ACE-2, Changes of serum ACE-2 at week 24 from baseline, 24 weeks|Renin, Changes of serum renin at week 24 from baseline, 24 weeks|Aldosterone, Changes of serum aldosterone at week 24 from baseline, 24 weeks|hsCRP, Changes of serum hsCRP at week 24 from baseline, 24 weeks|HbA1c, Change in HbA1c from baseline to week 24, 24 weeks|glucose, Change in fasting glucose from baseline to week 24, 24 weeks|Insulin, Change in fasting insulin from baseline to week 24, 24 weeks|FMD, Change in flow mediated vasodilatation (FMD) from baseline to week 24, 24 weeks|Microcirculation, Change in microcirculation from baseline to week 24, 24 weeks|TG, Change in triglycerides from baseline to week 24, 24 weeks|HDL, Change in HDL cholesterol from baseline to week 24, 24 weeks|LDL, Change in LDL cholesterol from baseline to week 24, 24 weeks
Sponsor/Collaborators: Sponsor: Seoul National University Bundang Hospital
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 80
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2021-01-01
Completion Date: 2023-06-30
Results First Posted:
Last Update Posted: 2023-08-14
Locations: Seoul National University Bundang Hospital, Seongnam, Gyeonggi, 463-707, Korea, Republic of
URL: https://clinicaltrials.gov/show/NCT05189015